[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Inhalation Drug Delivery Market - Forecasts from 2019 to 2024

March 2019 | 108 pages | ID: I3B2A59105DEN
Knowledge Sourcing Intelligence LLP

US$ 3,800.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The inhalation drug delivery market is projected to grow at a CAGR of 3.58% to reach US$ 43.011 billion by 2024, from US$ 34.828 billion in 2018. Inhalation drug delivery is referred to the transfer of drug into the human body through the lungs or it is also known as the pulmonary route of administration. These are available in either liquid or in powdered form. The market is poised to grow during the forecast period owing to the prevalence of asthma and COPD (Chronic Obstructive Pulmonary Disease). Furthermore, the growing geriatric population and growing health expenditure are emanating the market growth during the forecast period. Technological advancements will provide an opportunity for the growth of the global inhalation drug delivery market in the forecast period and beyond.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the inhalation drug delivery value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the inhalation drug delivery market.

Major industry players profiled as part of the report are GlaxoSmithKline group of companies, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Gerresheimer AG among others.

Segmentation

The inhalation drug delivery market has been analyzed through following segments:

By Technology
Dry powder inhaler
Metered dose inhaler
Nebulizer
Liquid inhaler

By Application
Disease Treatment
Research/Academic purposes

By Geography
North America
USA
Canada
Mexico
Others

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. INHALATION DRUG DELIVERY MARKET BY TECHNOLOGY

5.1. Dry powder inhaler
5.2. Metered dose inhaler
5.3. Nebulizer
5.4. Liquid inhaler

6. INHALATION DRUG DELIVERY MARKET BY APPLICATION

6.1. Disease Treatment
6.2. Research/Academic purposes

7. INHALATION DRUG DELIVERY MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. USA
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. United Kingdom
  7.3.4. Spain
  7.3.5. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. Israel
  7.4.3. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. Japan
  7.5.3. South Korea
  7.5.4. India
  7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Competitive Benchmarking and Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. GlaxoSmithKline group of companies
9.2. Merck & Co., Inc.
9.3. AstraZeneca
9.4. Boehringer Ingelheim International GmbH
9.5. Gerresheimer AG
9.6. Medisol Lifescience Pvt. Ltd
9.7. Cipla Limited
9.8. H&T Presspart Manufacturing Ltd.
LIST OF FIGURES
LIST OF TABLES


More Publications